t
PureTech Health plc's Chief Portfolio Officer, Robert Lyne, received 33,561 ordinary shares on 01 July 2025, priced at 0.01 pence per share, in settlement of restricted share units granted on 04 March 2024, of which 25% vested on 01 February 2025. On the same date, Mr. Lyne sold 33,561 ordinary shares at 125.05 pence per share and bought 33,561 ordinary shares into his SIPP at 125.78 pence per share.
| Date | 4 Jul 2025 |
| Time | 17:30:00 |
| Category | Director/PDMR dealings |
| ID | 7008P |
04 July 2025
PureTech Health plc
PDMR Notifications
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases, announces that award of restricted share units ("RSUs") granted by PureTech on 04 March 2024 to Robert Lyne, Chief Portfolio Officer ("PDMR") pursuant to its Performance Share Plan ("PSP") 25% of the shares vested on 01 February 2025.
The PDMR received vested ordinary shares (after deduction of shares for taxes) on 01 July 2025. The market price per ordinary share in the Company used to calculate the amount payable to the PDMR and the amount of shares to be issued to PDMR was 125.93 pence, being the average closing price of the Company's shares over the three-trading day period prior to issuance, and the exchange rate used to calculate the cash payment and amount of share settlement was £1: $1.37.
The Company has been notified that the PDMR has sold a total of 33,561 ordinary shares in the Company ("Shares") on 01 July 2025 at a price of 125.05 pence per share and bought on 01 July 2025, into his SIPP, a total of 33,561 Shares at the price of 125.78 pence per share.
The Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMR, 17,639,479 shares of which are held in treasury by the Company.
PDMR Notification
The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||||
|
a) |
Name |
Robert Lyne
|
||||||||
|
2 |
Reason for the notification |
|||||||||
|
a) |
Position/status |
Chief Portfolio Officer |
||||||||
|
b) |
Initial notification/Amendment |
Initial Notification |
||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
PureTech Health plc |
||||||||
|
b) |
LEI |
213800LVPDNO2Z9T9I39 |
||||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||
|
a) |
Description of the financial instrument, type of instrument |
|
||||||||
|
b) |
Nature of the transaction |
Issuance of ordinary shares in settlement of certain vested RSUs under the PureTech Health Performance Share Plan and Share Disposal |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
|
|
||||||||
|
e) |
Date of the transaction |
01 July 2025 |
||||||||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
||||||||
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Contact:
PureTech
Investor Relations